SK to target the KRW 1 trillion global market of sleep disorder treatments
SK Biopharmaceuticals announced on the 21st the company completed the NDA(New Drug Application) process to the U.S. FDA for SKL-N05(generic name: Solriamfetol) with U.S. Jazz Pharmaceuticals, the world’s leading company in the sleeping disorder market.
Once the FDA approves it, it is expected t...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
